Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylic Acid SCHEMBL9797879 | 0.87 | SMN1; SMN2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| Methacrylic Acid SCHEMBL7134600 | 0.87 | CHRNB2 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL11541989 | 0.87 | ALOX15 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL13083832 | 0.84 | TDP1 (0.58) | SMN1; SMN2MEN1MAPTKMT2AALOX15 | |
| SCHEMBL18591656 | 0.83 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL20052073 | 0.83 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL9639334 | 0.83 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL606534 | 0.82 | ALOX15 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL104010 | 0.82 | ALOX15 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL606445 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5360836-A | Acrylate of isopropyl beta-hydroxyethylcarbamate as reactive diluent | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1994-11-01 | — | — | US | claimed |
| EP-0263749-B1 | PROCESS FOR THE PREPARATION OF RADIOCROSSLINKED COATINGS | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1991-05-29 | — | — | EP | claimed |
| US-11827586-B2 | Method for producing amino acid aminoalkyl ester or inorganic acid salt thereof | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-11-28 | — | — | US | disclosed |
| US-11827586-B2 | Method for producing amino acid aminoalkyl ester or inorganic acid salt thereof | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-11-28 | — | — | US | disclosed |
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | EVOTEC (FRANCE) SAS (FR) | 2023-01-19 | — | — | US | disclosed |
| US-20220267352-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-25 | — | — | US | disclosed |
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20100048513-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2010-02-25 | — | — | US | disclosed |
| WO-2009121872-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009024611-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | disclosed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| US-5360836-A | Acrylate of isopropyl beta-hydroxyethylcarbamate as reactive diluent | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1994-11-01 | — | — | US | disclosed |
| US-5360836-A | Acrylate of isopropyl beta-hydroxyethylcarbamate as reactive diluent | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1994-11-01 | — | — | US | disclosed |
| US-4874857-A | FIBER-REACTIVE DYES | BAYER AKTIENGESELLSCHAFT (DE) | 1989-10-17 | — | — | US | disclosed |
| US-4165384-A | ADRENERGIC BLOCKING AGENTS, CARDIOVASCULAR DISORDERS | AKTIEBOLAGET HASSLE (SE) | 1979-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048513-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CHRNB2 3577/4885CHRNB4 3847/4885CHRNA3 4233/4885 |
| US-20220267352-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | CHRNB2 4877/4885CHRNB4 4866/4885CHRNA3 4868/4885 |
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | CHRNB2 4814/4885CHRNB4 4831/4885CHRNA3 4838/4885 |
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | CHRNB2 4814/4885CHRNB4 4831/4885CHRNA3 4838/4885 |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | CHRNB2 4829/4885CHRNB4 4832/4885CHRNA3 4862/4885 |
| US-20090036409-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CHRNB2 3577/4885CHRNB4 3847/4885CHRNA3 4233/4885 |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | CHRNB2 4814/4885CHRNB4 4831/4885CHRNA3 4838/4885 |
| US-11827586-B2 | Method for producing amino acid aminoalkyl ester or inorganic acid salt thereof | SLC6A15, SLC6A19, ALAD | CHRNB2 4651/4885CHRNB4 4282/4885CHRNA3 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.